{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Settles EW"],"funding":["Defense Threat Reduction Agency","Arizona Technology and Research Initiative Fund","Australian National Health and Medical Research Council"],"pagination":["e0011072"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9907819"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(2)"],"pubmed_abstract":["Burkholderia pseudomallei, the causative agent of melioidosis, is a gram-negative soil bacterium well recognized in Southeast Asia and northern Australia. However, wider and expanding global distribution of B. pseudomallei has been elucidated. Early diagnosis is critical for commencing the specific therapy required to optimize outcome. Serological testing using the indirect hemagglutination (IHA) antibody assay has long been used to augment diagnosis of melioidosis and to monitor progress. However, cross reactivity and prior exposure may complicate the diagnosis of current clinical disease (melioidosis). The goal of our study was to develop and initially evaluate a serology assay (BurkPx) that capitalized upon host response to multiple antigens. Antigens were selected from previous studies"],"journal":["PLoS neglected tropical diseases"],"pubmed_title":["Development and evaluation of a multiplex serodiagnostic bead assay (BurkPx) for accurate melioidosis diagnosis."],"pmcid":["PMC9907819"],"funding_grant_id":["1046812","HDTRA1-12-C-0022","1131932","1098337"],"pubmed_authors":["Mayo M","Sonderegger D","Mbegbu M","Hornstra H","Celona KR","Woerle C","Currie BJ","Settles EW","Yi J","Lederer R","Keim P","Headley K","Allender C","Seavey C","Shannon AB","Harvey M","Keener M","Monroy FP","Theobald V"],"additional_accession":[]},"is_claimable":false,"name":"Development and evaluation of a multiplex serodiagnostic bead assay (BurkPx) for accurate melioidosis diagnosis.","description":"Burkholderia pseudomallei, the causative agent of melioidosis, is a gram-negative soil bacterium well recognized in Southeast Asia and northern Australia. However, wider and expanding global distribution of B. pseudomallei has been elucidated. Early diagnosis is critical for commencing the specific therapy required to optimize outcome. Serological testing using the indirect hemagglutination (IHA) antibody assay has long been used to augment diagnosis of melioidosis and to monitor progress. However, cross reactivity and prior exposure may complicate the diagnosis of current clinical disease (melioidosis). The goal of our study was to develop and initially evaluate a serology assay (BurkPx) that capitalized upon host response to multiple antigens. Antigens were selected from previous studies","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-08-13T03:04:20.463Z","creation":"2025-04-04T23:52:41.375Z"},"accession":"S-EPMC9907819","cross_references":{"pubmed":["36753506"],"doi":["10.1371/journal.pntd.0011072"]}}